Search Results - "Karsh, L.I."

1777P Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints by De Giorgi, U.F.F., Freedland, S.J., Gleave, M.E., Tutrone, R., Bailen, J.L., Roos, E., Kliment, J., Marx, G.M., Karsh, L.I., Ramirez-Backhaus, M., Uchio, E., Supiot, S., Tang, Y., Rosbrook, B., Haas, G.P., Rosales, M., Zohren, F., Shore, N.D.

Get full text

610P BXCL701 - 1st-in-class oral activator of systemic innate immunity-combined with pembrolizumab, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase II results by Monk, P., Zhang, J., Costin, D., Petrylak, D.P., Tagawa, S.T., Karsh, L.I., Zhu, X., Linch, M., Jones, R., Borderies, P., O'Neill, V., Aggarwal, R.R.

Get full text

Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial by Boorjian, S.A., Narayan, V.M., Konety, B.R., Master, V.A., Shore, N.D., Kamat, A.M., Bivalacqua, T.J., Kates, M.R., Montgomery, J.S., Crispen, P.L., Steinberg, G.D., Agarwal, P.K., Schuckman, A.K., Karsh, L.I., Bjurlin, M.A., Brown, G.A., Lotan, Y., Inman, B.A., Williams, M.B., Cookson, M.S., Chang, S.S., Kim, E.H., Sankin, A.I., Dinney, C.

Get full text

A0583 - Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial by Boorjian, S.A., Narayan, V.M., Konety, B.R., Master, V.A., Shore, N.D., Kamat, A.M., Bivalacqua, T.J., Kates, M.R., Montgomery, J.S., Crispen, P.L., Steinberg, G.D., Agarwal, P.K., Schuckman, A.K., Karsh, L.I., Bjurlin, M.A., Brown, G.A., Lotan, Y., Inman, B.A., Williams, M.B., Cookson, M.S., Chang, S.S., Kim, E.H., Sankin, A.I., Dinney, C.

Get full text

1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC) by Sandhu, S.K., Gotto, G., Vera-Badillo, F.E., Byun, S-S., Cutuli, H.J., Gomes, A.J.P.D.S., Helissey, C., Karsh, L.I., Peer, A., Preto, D.D., Pu, Y-S., Ravilla, R., Roubaud, G., Skoneczna, I.A., Kim, W., Espina, B., Withelder, M., Urtishak, K., Francis, P.S.J., Saad, F.

Get full text

1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status by Matsubara, N., Fizazi, K., Azad, A.A., Carles Galceran, J., Fay, A.P., De Giorgi, U.F.F., Joung, J.Y., Fong, P.C., Voog, E., Jones, R.J., Shore, N.D., Dunshee, C., Zschäbitz, S., Karsh, L.I., Barthelemy, P., Lin, X., Healy, C.G., Di Santo, N., Zohren, F., Agarwal, N.

Get full text

618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN by Shen, J., Chowdhury, S., Agarwal, N., Karsh, L.I., Oudard, S., Gartrell, B.A., Feyerabend, S., Saad, F., Pieczonka, C.M., Chi, K.N., Brookman-May, S.D., Rooney, B., Bhaumik, A., Londhe, A., McCarthy, S.A., Bevans, K.B., Mundle, S.D., Small, E.J., Smith, M.R., Graff, J.N.

Get full text

980 A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC): Immune results with a focus on humoral responses by Antonarakis, E.S, Kibel, A.S, Adams, G.W, Karsh, L.I, Elfiky, A, Shore, N.D, Vogelzang, N.J, Corman, J.M, Tyler, R.C, McCoy, C, DeVries, T, Sheikh, N, Drake, C.G

Get full text

775PA RANDOMIZED PHASE 2 STUDY EVALUATING OPTIMAL SEQUENCING OF SIPULEUCEL-T (SIP-T) AND ANDROGEN DEPRIVATION THERAPY (ADT) IN BIOCHEMICALLY-RECURRENT PROSTATE CANCER (BRPC): VARIABLES THAT CORRELATE WITH IMMUNE RESPONSE by Drake, C.G., Kibel, A.S., Adams, G.W., Karsh, L.I., Elfiky, A., Shore, N.D., Vogelzang, N.J., Corman, J.M., Tyler, R.C., McCoy, C., Devries, T., Sheikh, N., Antonarakis, E.S.

“…Abstract Aim: Sip-T is an autologous cellular immunotherapy targeting prostatic acid phosphatase (PAP) approved by the US FDA and EMA for treatment of certain…”
Get full text

A Randomized Phase 2 Study Evaluating Optimal Sequencing of Sipuleucel-T (Sip-T) and Androgen Deprivation Therapy (Adt) in Biochemically-Recurrent Prostate Cancer (Brpc): Variables that Correlate with Immune Response by Drake, C.G., Kibel, A.S., Adams, G.W., Karsh, L.I., Elfiky, A., Shore, N.D., Vogelzang, N.J., Corman, J.M., Tyler, R.C., McCoy, C., Devries, T., Sheikh, N., Antonarakis, E.S.

Get full text